Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Systems, methods, and computer readable mediums for configuring a radio system to provide network service access based on a location of the radio system. The radio system can identify the location and send a location signal indicating its location over a first network. The radio system can receive, over the first network, first configuration data for communicating over a second network based on its location. The radio system can configure itself to communicate over the second network using the first configuration data and subsequently provide network service access over the second network according to the first configuration data.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: A casing exit joint with guiding profiles and methods for use are provided. In one embodiment, a casing exit joint comprises: a substantially tubular casing joint comprising an inner surface and an outer surface, wherein at least a circumferential portion of the inner surface comprises a plurality of axial inner grooves. In certain embodiments, at least a circumferential portion of the outer surface may comprise a plurality of axial outer grooves. The casing exit joint may be disposed in a wellbore penetrating at least a portion of a subterranean formation, and a cutting tool may cut a window through at least a portion of the casing exit joint. In certain embodiments, the axial inner grooves and/or outer grooves may reduce the amount of milling debris, prevent lateral displacement of the cutting tool, and/or eliminate the need to pre-orient the casing exit joint to achieve the desired exit window.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: In some aspects, a downhole assembly is provided that can include a window joint positioned within a tubular element and a bypass restrictor. The bypass restrictor can be positioned in an annulus between an outer surface of the window joint and an inner surface of the tubular element. The bypass restrictor can restrict the flow of a pressurized fluid via the annulus from a first end to a second end of a wiper plug.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: Systems, methods, and non-transitory computer-readable storage media for using mobile network authentication factors to authenticate a mobile device.

Abstract: Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Abstract: A folding wing having a wing tip device (3) rotatable between flight and ground configurations, about an Euler axis of rotation (11). The wing tip device (3) and a fixed wing (1) are separated along an oblique cut plane (13) passing through the upper and lower surfaces of the folding wing. A rotational joint (15) for coupling the wing tip device (3) to the fixed wing (1) during rotation between the ground and flight configurations. The rotational joint includes a follower (17a) and a guide (17b), one which being fixed relative to the wing tip device and the other being fixed relative to the fixed wing. The follower and guide interlock such as by interlocking rings. The follower is received in the guide such that during rotation between the ground and flight configurations the follower moves along the arcuate path defined by the guide.